The Next Generation of COVID-19 Vaccines

The Next Generation of COVID-19 Vaccines

Drug Companies Develop Vaccines in the Form of Nasal Sprays and Pills

A handful of drug companies including Sanofi (SNY), Altimmune (ALT), Vaxart (VXRT) and Gritstone Oncology (GRTS) are developing a new crop of COVID-19 vaccines which may be available in the form of pills or nasal sprays.

The next generation of vaccines could produce longer-lasting results and may work better against new variants of the disease. US government-backed labs are also working on COVID-19 vaccines which are easier to transport and store.

Distribution of the new vaccines could be logistically simpler because they won’t have to be transported and stored at low temperatures. This would have a number of benefits, including that it would mean people in rural areas could receive vaccines more easily.

New Vaccines Could Be Available This Year

As it stands, about 277 COVID-19 vaccines are in development with 93 in human testing. Of those, two are in the form of an oral pill and seven are nasal sprays. Many of the drug companies are in the early or middle phases of human testing.

Altimmune is working on a vaccine which is administered as a nasal spray. The drug company expects results of an early-stage study by midyear. Meanwhile, Vaxart is developing a digestible tablet. An early-stage study of the pill showed that it triggered immune responses to COVID-19.

If the vaccinations prove effective, they could become available later this year or next year. They could serve as a booster for inoculated people in the US and as the primary vaccination for countries which may still be in the process of immunizing their populations later this year and next year.

Booster Shots Will Likely Be Needed

The development of new COVID-19 vaccines comes as infectious diseases specialists predict boosters will be required to extend the effectiveness of vaccines and to fight other variants. Researchers are also examining whether giving doses of two different vaccines will boost defenses.

The Walter Reed Army Institute of Research recently started clinical trials of a vaccine which protects against COVID-19 variants. Researchers want to develop a single shot to immunize people against variants. As the world begins to emerge from lockdowns, scientists are still hard at work determining how to keep people safe from COVID-19 going forward.

Things are changing daily within the financial world. Sign up for the SoFi Daily Newsletter to get the latest news updates in your inbox every weekday.

Sign up

Please understand that this information provided is general in nature and shouldn’t be construed as a recommendation or solicitation of any products offered by SoFi’s affiliates and subsidiaries. In addition, this information is by no means meant to provide investment or financial advice, nor is it intended to serve as the basis for any investment decision or recommendation to buy or sell any asset. Keep in mind that investing involves risk, and past performance of an asset never guarantees future results or returns. It’s important for investors to consider their specific financial needs, goals, and risk profile before making an investment decision.
The information and analysis provided through hyperlinks to third party websites, while believed to be accurate, cannot be guaranteed by SoFi. These links are provided for informational purposes and should not be viewed as an endorsement. No brands or products mentioned are affiliated with SoFi, nor do they endorse or sponsor this content.
Communication of SoFi Wealth LLC an SEC Registered Investment Adviser
SoFi isn’t recommending and is not affiliated with the brands or companies displayed. Brands displayed neither endorse or sponsor this article. Third party trademarks and service marks referenced are property of their respective owners.

All your finances.
All in one app.

SoFi QR code, Download now, scan this with your phone’s camera

All your finances.
All in one app.

App Store rating

SoFi iOS App, Download on the App Store SoFi Android App, Get it on Google Play

ABOUT Meg Richardson Meg Richardson is a writer specializing in markets, technology, and personal finance. She loves breaking down seemingly complex ideas and making them readable and interesting for everyone. She holds an MFA in writing from Columbia University. When she is not writing about finance, she enjoys running in Central Park and drawing cartoons.

TLS 1.2 Encrypted
Equal Housing Lender